Assembly Biosciences (ASMB) Commences ABI-H0731 Phase 1 as HBV Treatment
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Assembly Biosciences Initiates Phase 1 Clinical Program of ABI-H0731 for Treatment of Chronic Hepatitis B Virus Infection
November 9, 2016 7:05 AM ESTINDIANAPOLIS, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral biotherapeutics for disorders associated with the microbiome, today announced initiation of a Phase 1a/1b clinical trial of ABI-H0731, its initial Core protein Allosteric Modifier (CpAM) for the treatment of chronic HBV.
The Phase 1a study will assess the safety, tolerability and pharmacokinetics of ABI-H0731 in healthy volunteers. Subsequently, a Phase 1b study will assess the safety, pharmacokinetics... More